Table 3.

Response to nivolumab in 24 patients with measurable disease according to the potential predictive biomarkers

	Objective response rate (n, %)	Disease control rate (n, %)
Baseline blood NLR
> 2.9 (n = 14)	1 (7.1)	5 (35.7)
≤ 2.9 (n = 10)	3 (30)	6 (60.0)
Baseline serum Na
< 135 mmol/L (n = 4)	0 (0.0)	1 (25.0)
≥ 135 mmol/L (n = 20)	4 (20.0)	10 (50.0)
Tumor PD-L1
CPS < 1% (n = 10)	1 (10.0)	2 (20.0)
CPS ≥ 1% (n = 8)	3 (37.5)	7 (87.5)
CPS ≥ 10% (n = 2)	1 (50.0)	2 (100.0)
Tumor EBV
Negative (n = 13)	3 (23.1)	6 (46.2)
Positive (n = 5)	1 (20.0)	3 (60.0)
Tumor mutation burden
≤ 8.2/Mb (n = 6)	1 (16.7)	3 (50.0)
> 8.2/Mb (n = 6)	2 (33.3)	3 (50.0)

NLR Neutrophil–lymphocyte ratio, EBV Epstein-Barr Virus